These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 9484869

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [Grepafloxacin (Raxar)].
    Friis HM.
    Ugeskr Laeger; 1998 Jul 20; 160(30):4438-41. PubMed ID: 9691842
    [No Abstract] [Full Text] [Related]

  • 26. The fluoroquinolones after ciprofloxacin and ofloxacin.
    Hooper DC.
    Curr Clin Top Infect Dis; 2000 Jul 20; 20():63-91. PubMed ID: 10943519
    [No Abstract] [Full Text] [Related]

  • 27. A critical review of the fluoroquinolones: focus on respiratory infections.
    Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, Smith H, Hoban DJ.
    Drugs; 2002 Jul 20; 62(1):13-59. PubMed ID: 11790155
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The fluoroquinolones.
    Walker RC.
    Mayo Clin Proc; 1999 Oct 20; 74(10):1030-7. PubMed ID: 10918871
    [Abstract] [Full Text] [Related]

  • 30. Comparative grepafloxacin phototoxicity in mouse skin.
    Owen K.
    J Antimicrob Chemother; 1998 Aug 20; 42(2):261-4. PubMed ID: 9738848
    [Abstract] [Full Text] [Related]

  • 31. The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice.
    Yoshizumi S, Takahashi Y, Murata M, Domon H, Furuya N, Ishii Y, Matsumoto T, Ohno A, Tateda K, Miyazaki S, Yamaguchi K.
    J Antimicrob Chemother; 2001 Jul 20; 48(1):137-40. PubMed ID: 11418525
    [Abstract] [Full Text] [Related]

  • 32. Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.
    Paton JH, Reeves DS.
    Drugs; 1988 Aug 20; 36(2):193-228. PubMed ID: 3053126
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Quinolones: clinical use and formulary considerations.
    Cunha BA.
    Adv Ther; 1998 Aug 20; 15(5):277-87. PubMed ID: 10345149
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Ultrastructural characterization of murine limb buds after in vitro exposure to grepafloxacin and other fluoroquinolones.
    Shakibaei M, Baumann-Wilschke I, Rücker M, Stahlmann R.
    Arch Toxicol; 2002 Jan 20; 75(11-12):725-33. PubMed ID: 11876506
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.